Allergy Therapeutics PLC Grant of Awards (1108T)
December 30 2016 - 9:31AM
UK Regulatory
TIDMAGY
RNS Number : 1108T
Allergy Therapeutics PLC
30 December 2016
30 December 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the 'Company")
Grant of Awards under Long Term Incentive Plan
Allergy Therapeutics (AIM:AGY), the fully integrated
pharmaceutical company specialising in allergy vaccines, announces
that, pursuant to the Company's Long Term Incentive Plan ("LTIP")
the following conditional awards of shares of 0.1 pence each were
made to Executive Directors at nominal cost of 0.1 pence each on 30
December 2016.
Executive Director Number of Conditional Total conditional
shares awarded shares held under
LTIPs
-------------------- ---------------------- -------------------
Manuel Llobet 1,690,000 3,380,000
-------------------- ---------------------- -------------------
Nick Wykeman 422,500 422,500
-------------------- ---------------------- -------------------
The issuance and distribution of ordinary shares of 0.1 pence
each under the LTIP is conditional on the satisfaction of
performance conditions which include an earnings growth test over a
three year testing period to 30 June 2019 and share price growth
over the 3 year plan cycle.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial
responsibilities / person closely associated
---- ------------------------------------------------------------
a) Name Manuel Llobet
Nicolas Wykeman
---- ------------------- ---------------------------------------
2 Reason for the notification
Grant of conditional awards of 0.1 pence each
---- ------------------------------------------------------------
a) Position/status Manual Llobet - Chief Executive Office
Nicolas Wykeman - Finance Director
---- ------------------- ---------------------------------------
b) Initial Initial notification
notification
/Amendment
---- ------------------- ---------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
---- ------------------------------------------------------------
a) Name ALLERGY THERAPEUTICS PLC
---- ------------------- ---------------------------------------
b) LEI
---- ------------------- ---------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
---- ------------------------------------------------------------
a) Description Conditional award of shares under
of the financial the Company's Long Term Incentive
instrument, Plan
type of
instrument
Identification
code
---- ------------------- ---------------------------------------
b) Nature of
the transaction
---- ------------------- ---------------------------------------
Price(s)
c) and volume(s) 1,690,000
---- ------------------- ---------------------------------------
d) Aggregated
information
- Aggregated
volume
- Price
---- ------------------- ---------------------------------------
e) Date of 30 December 2016
the transaction
---- ------------------- ---------------------------------------
f) Place of Outside a trading venue
the transaction
---- ------------------- ---------------------------------------
Name of authorised official of issuer responsible for making
notification:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate
Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan
allergytherapeutics@consilium-comms.com
Note to editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical company focussed on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that cure
disease. The Company sells proprietary products and third party
products from its subsidiaries in nine major European countries and
via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with MHRA-approved manufacturing
facilities. The Company employs c.420 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHZBLFXQLFLFBD
(END) Dow Jones Newswires
December 30, 2016 09:31 ET (14:31 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Sep 2023 to Sep 2024